| Name | Title | Contact Details |
|---|---|---|
John Bishop |
Chief Technology Officer | Profile |
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
Gala Design Inc is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.
Path-Tec is a leading provider of specimen collection kits and components. Our specialty is detailed specimen management. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen co...